Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (7954)	6/5/1998 2:41:00 AM
From: scaram(o)uche	Respond to of 9262

Scott: I bought AGPH in 12/94 at $5, split adjusted, and sold at $46. Did some trading along the way to make it a fairly quick 10 bagger plus. Just recently went back in with a modest call position. LGD doesn't react to positive news because veteran biotech investors know that Robinson funds the company and expands the breadth of research at the expense of his shareholders. I sold at $17 two years ago, correctly predicting that dilution was coming (but never picturing how out of hand it would get). I'm also not a TA type, and rely on Ray, Rainier et al. for insight there. However, I doubt that LND will make it south of $12. My top two or three based on those criteria? Well, I rarely pay any attention to the "stage of clinical development" part..... I primarily invest in early-stage companies, and have only stayed with AGPH and GLIA to later stages. Two of my three favorites are low volume issues, and I'd therefore like to keep them close to vest for awhile. However, the third is MLNM. Cheers! Rick